Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol CHUK contributors: mct - updated : 09-11-2015
HGNC name conserved helix-loop-helix ubiquitous kinase
HGNC id 1974
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
21 - 3539 - 745 - 2006 17102620
EXPRESSION
Type ubiquitous
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Cardiovascularheart   moderately
Lymphoid/Immunelymph node   highly
Urinarykidney   highly
cells
SystemCellPubmedSpeciesStageRna symbol
Lymphoid/ImmuneT cell
cell lineage
cell lines cervical carcinoma
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • serine/threonine kinase domain
  • a leucine zipper domain
  • a conserved region in the C-terminal tail, (NEMO-binding domain, NBD) important for interaction with IKBKG (Lo 2008)
  • conjugated PhosphoP
    mono polymer homomer , heteromer , dimer
    HOMOLOGY
    interspecies ortholog to murine Chuk
    Homologene
    FAMILY Ser/Thr family of protein kinases
    CATEGORY enzyme , regulatory , protooncogene
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm,cytosolic
    intracellular,nucleus
    basic FUNCTION
  • deactivating the inhibitor of kappa light polypeptide enhancer in B cells (NFKB)
  • phosphorylating sites that trigger the degradation of the inhibitor via the ubiquination pathway, thereby activating the transcription factor
  • is an essential regulator of NFKB-dependent gene expression through control of promoter-associated histone phosphorylation after cytokine exposure
  • involved in the negative regulation of macrophage activation and inflammation
  • promoting recombinase activator genes (RAG) transcription
  • playing a major role in regulating the biological effects of estrogen via its promoter association
  • controlling skeletal and craniofacial morphogenesis by repressing expression of fibroblast growth factor (FGF) family members, such as FGF8
  • having an important role in the activation of nuclear factor-kB (NF-kB), a key regulator of normal and tumor cell proliferation, apoptosis, and response to chemotherapy
  • playing a potential role in bile duct disease
  • functioning as a molecular switch that controls epidermal differentiation
  • functions as a tumor suppressor in human squamous cell carcinomas (SCCs) of skin, lungs, and head and neck
  • CHUK and alkaline phosphatase are negative regulators of IRF5 activity in MYD88 pathway and have role in the control of the inflammatory response by attenuation of IRF5 activity
  • plays a critical role in mediation of the UVB-induced G0/G1 cell cycle arrest response by suppressing Cyclin D1 expression
  • role of IKKalpha in regulating cell cycle progression during the cellular UVB response
  • key mediator of the inflammation and metastasis in prostate cancer, playing a major role in prostate cancer invasion and metastasis, but not in cell proliferation
  • RIPK4 and CHUK might function via closely related pathways to promote keratinocyte differentiation and epithelial growth 8)
  • IKBKG together with the catalytic subunits CHUK and IKBKB, plays an essential role in the formation of the IKK complex and in the activation of the canonical NFKB pathway
  • CELLULAR PROCESS cell life, differentiation
    PHYSIOLOGICAL PROCESS development , immunity/defense
    text
  • immune response
  • embryogenesis, morphogenesis
  • PATHWAY
    metabolism
    signaling
    a component
  • preferentially complexing with IKBKB, but also forming homodimer
  • component of a cytokine-activated protein complex (NCOA2, NCOA3, IKKB, IKBKG and CREBBP)
  • IKBKG together with catalytic subunits CHUK and IKBKB, forms the IKB kinase (IKK) complex, a key regulator of NFKB pathway signaling
  • INTERACTION
    DNA
    RNA
    small molecule nucleotide,
    ATP binding
    protein
  • interacting with MEKK1, NEMO, TRPC4AP, NALP2, MAVS/IPS1
  • interacting with CREBP
  • regulating the M phase of the cell cycle by modulating Aurora A phosphorylation
  • cooperating with IKBKB for regulating liver immune homeostasis and bile duct integrity (share a redundant function in mediating canonical NFKB signaling in hepatocytes and protecting the liver from TNF toxicity)
  • CHUK and alternative NFKB regulate PPARGC1B to promote oxidative muscle metabolism
  • NFKB1 signaling pathway, which involves both NFKBIA and CHUK, plays an important role in platelet CD40 signaling, activation and aggregation in response to sCD40LG
  • UBE2N-CHUK signaling axis regulates the molecular program that maintains Treg cell function and prevents Treg cells from acquiring inflammatory phenotypes
  • IKBKG is essential for IKBKB activation by inflammatory stimuli, and also a specificity factor that directs IKBKB activity toward CHUK
  • CHUK and IKBKB physically interacted with RICTOR
  • CHUK and IKBKB are RELB interacting partners whose activation by TNF promotes RELB phosphorylation at serine 472
  • CHUK controls the inflammasome at the level of the adaptor PYCARD, which interacts with CHUK in the nucleus of resting macrophages in an CHUK kinase-dependent manner
  • cell & other
    REGULATION
    activated by phosphorylation
    Other phosphorylated by MAP3K14/NIK, AKT and to a lesser extent by MEKK1, and dephosphorylated by PP2A
    autophosphorylated
    ASSOCIATED DISORDERS
    corresponding disease(s) COCS
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional   deletion    
    protecting against neurodegeneration in cerebral ischemia
    constitutional       loss of function
    in exon 15
    tumoral     --low  
    provides a selective growth advantage that cooperates with Ras activity to promote skin carcinogenesis
    Susceptibility to squamous cell carcinomas
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancer  
    targeting CHUK might be promising for the prevention of UVB-induced cell damage and tumorigenic effects
    miscelleaneous  
    CHUK inhibitor for stroke therapy
    cancer  
    loss of TP53-mediated control over ETS1-dependent transactivation of CHUK may represent a novel pathway for the constitutive activation of NF-kB-mediated gene expression and therapy resistance in cancer
    cancerreproductiveprostate
    silencing of CHUK with siRNA may therefore provide a promising therapeutic strategy for prostate cancer patients
    cancerdigestiveliver
    IKK-targeted gene therapy can be used in the treatment of hepatocellular carcinoma, a cancer that is notoriously resistant to radiation and chemotherapy
    ANIMAL & CELL MODELS
  • Ikkalpha(-/-) mice present with a hyperproliferative and undifferentiated epidermis characterized by complete absence of a granular layer and stratum corneum (Descarques, 2008)